Spain to reimburse Intelence
This article was originally published in Scrip
Spain is to reimburseTibotec's Intelence (etravirine) for HIV patients who have failed on other antiretrovirals. 2,000 patients in Spain could benefit from the non-nucleoside reverse transcriptase inhibitor, which has a manufacturer's selling price of €450 there, says the health ministry. It will be dispensed in hospitals in 200mg doses. The European Commission approved Intelence in August and the company has since launched the drug in Germany, Austria, France, the UK, Finland, Denmark, Sweden and Poland. Outside the EU, Switzerland, Russia, Liechtenstein, the US, Canada, Mexico, Argentina, Colombia, Bolivia, Australia, Hong Kong and South Korea have also approved the drug. Tibotec is part ofJohnson & Johnson.
You may also be interested in...
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.